Key result
REMADI successfully reduces mitral annulus diameter in a beating porcine heart model.
Why the study?
Outcomes of mitral annuloplasty ring implantation for mitral regurgitation are variable, and recurrent mitral regurgitation is not uncommon.
A novel reshapeable mitral annuloplasty device demonstrated feasibility for deployment and annulus reduction in a preclinical porcine model.
Preclinical feasibility in porcine model warrants human trials; leaves open safety and efficacy for mitral regurgitation repair.
Surgical repair with implantation of a mitral annuloplasty ring is the gold standard treatment for mitral regurgitation. However, outcomes are variable and recurrent mitral regurgitation is not uncommon. A REshapeable Mitral Annuloplasty DevIce (REMADI) is proposed, which consists of a fully encapsulated low melting temperature alloy. The alloy is solid and rigid at body temperature and provides traction force to shape the annulus. When heated using a noncontact method, the alloy melts and the REMADI becomes malleable. The REMADI is engaged with the mitral valve annulus using anchors which automatically deploy upon contact. A passive beating porcine heart model was used to demonstrate the feasibility of the REMADI device, which was deployed, engaged, and used to reduce the diameter of the mitral valve annulus.
No takes yet. Share an insight, caveat, or question.
Brubert et al. (2020) studied Mitral regurgitation. REshapeable Mitral Annuloplasty DevIce (REMADI) was evaluated on Feasibility of device deployment, engagement, and reduction of mitral valve annulus diameter. The REshapeable Mitral Annuloplasty DevIce (REMADI) was successfully deployed, engaged, and used to reduce the diameter of the mitral valve annulus in a passive beating porcine heart model.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: